Learn languages naturally with fresh, real content!

Popular Topics
Explore By Region
Cardiol Therapeutics raises $13.5M in financing to advance its heart disease drug, CardiolRx™.
Cardiol Therapeutics Inc. announced a bought deal financing to raise $13.5 million, selling 10.4 million units at $1.30 each, with each unit including one share and half a warrant to buy another at $1.75 within 24 months.
The underwriter may purchase an additional 10% of units, potentially raising up to $1.35 million more.
The deal, expected to close Jan. 23, 2026, is subject to regulatory approvals and will fund research, clinical development, and general expenses for its heart disease drug candidate, CardiolRx™.
The offering is exempt from U.S. registration and available to qualified investors in Canada and certain U.S. investors under exemptions.
Cardiol Therapeutics recauda $13.5M en financiamiento para avanzar en su medicamento para enfermedades cardíacas, CardiolRxTM.